SOPHiA Genetics SA Long Term Debt

SOPHiA Genetics SA (SOPH) currently reports a long-term debt of $60M as of March 2026. That compares with $28M in the prior-year period — up 114.5% year over year. Use the charts on this page to explore SOPHiA Genetics SA's long-term debt history and peer comparisons.

SOPHiA Genetics SA's long-term debt increased from $28M to $60M — a 114.5% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

SOPHiA Genetics SA reported $60M in long-term debt as of March 2026. That compares with $28M in the prior-year period — up 114.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $60M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for SOPHiA Genetics SA, and consider following SOPH for alerts when major investors trade the stock.

SOPHiA Genetics SA is classified in the Healthcare sector. On long-term debt, it currently shows $60M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SOPH with unrelated industries.